Clinical TrialJun 16, 2026, 07:02 AM
Invivyd Completes Enrollment for Phase 3 LIBERTY Trial; Data Q3 2026
AI Summary
Invivyd, Inc. announced the completion of enrollment for its Phase 3 LIBERTY clinical trial, which compares the safety and tolerability of its investigational COVID-19 monoclonal antibody VYD2311 with an mRNA COVID-19 vaccine. The company expects to report topline data from the study in the third quarter of 2026. VYD2311 is being developed as a potential alternative to vaccines for preventing COVID-19, with the aim of offering an improved side effect profile and tolerability advantage.
Key Highlights
- Invivyd completed enrollment for its Phase 3 LIBERTY clinical trial.
- Topline data from the LIBERTY study is expected in Q3 2026.
- The LIBERTY trial compares VYD2311 with an mRNA COVID-19 vaccine.
- Primary endpoint is to assess side effects and tolerability through Day six.
- The LIBERTY study enrolled approximately 210 participants.
- VYD2311 is part of the REVOLUTION clinical program, including DECLARATION with 2,400 participants.
Price Impact
More from IVVD